EA002244B1 - Композиции для управления образованием бактериальных колоний - Google Patents
Композиции для управления образованием бактериальных колоний Download PDFInfo
- Publication number
- EA002244B1 EA002244B1 EA200000422A EA200000422A EA002244B1 EA 002244 B1 EA002244 B1 EA 002244B1 EA 200000422 A EA200000422 A EA 200000422A EA 200000422 A EA200000422 A EA 200000422A EA 002244 B1 EA002244 B1 EA 002244B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- anchor
- enzyme
- composition
- bacterial
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 208000034309 Bacterial disease carrier Diseases 0.000 title abstract 5
- 102000004190 Enzymes Human genes 0.000 claims abstract description 178
- 108090000790 Enzymes Proteins 0.000 claims abstract description 178
- 230000001580 bacterial effect Effects 0.000 claims abstract description 65
- 210000000214 mouth Anatomy 0.000 claims abstract description 65
- 241000894006 Bacteria Species 0.000 claims abstract description 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 40
- 150000004676 glycans Chemical class 0.000 claims abstract description 37
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 36
- 239000005017 polysaccharide Substances 0.000 claims abstract description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 36
- 239000011159 matrix material Substances 0.000 claims abstract description 35
- 229920001184 polypeptide Polymers 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 33
- 239000000758 substrate Substances 0.000 claims abstract description 26
- 230000012010 growth Effects 0.000 claims abstract description 24
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims abstract description 15
- 229920001503 Glucan Polymers 0.000 claims abstract description 14
- 238000010504 bond cleavage reaction Methods 0.000 claims abstract description 13
- 229930006000 Sucrose Natural products 0.000 claims abstract description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 12
- 230000002378 acidificating effect Effects 0.000 claims abstract description 12
- 239000005720 sucrose Substances 0.000 claims abstract description 12
- 239000012634 fragment Substances 0.000 claims abstract description 11
- 235000000346 sugar Nutrition 0.000 claims abstract description 11
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 10
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 10
- 150000002632 lipids Chemical class 0.000 claims abstract description 9
- 150000002482 oligosaccharides Polymers 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 9
- 125000002091 cationic group Chemical group 0.000 claims abstract description 7
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 7
- 230000007017 scission Effects 0.000 claims abstract description 7
- 108010001682 Dextranase Proteins 0.000 claims abstract description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 6
- -1 N-actylglucosamine Chemical compound 0.000 claims abstract description 6
- 210000004102 animal cell Anatomy 0.000 claims abstract description 6
- 125000000129 anionic group Chemical group 0.000 claims abstract description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- 150000002337 glycosamines Chemical class 0.000 claims abstract description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 6
- 239000012528 membrane Substances 0.000 claims abstract description 6
- 230000003278 mimic effect Effects 0.000 claims abstract description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 5
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 5
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 claims abstract description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- 229920001577 copolymer Polymers 0.000 claims abstract description 5
- 239000008103 glucose Substances 0.000 claims abstract description 5
- 229930091371 Fructose Natural products 0.000 claims abstract description 4
- 239000005715 Fructose Substances 0.000 claims abstract description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 4
- 108090000604 Hydrolases Proteins 0.000 claims abstract description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 claims abstract description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 claims abstract description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 claims abstract description 4
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 4
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims abstract description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims abstract description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 3
- 108010004103 Chylomicrons Proteins 0.000 claims abstract description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 3
- 102000016942 Elastin Human genes 0.000 claims abstract description 3
- 108010014258 Elastin Proteins 0.000 claims abstract description 3
- 108090000371 Esterases Proteins 0.000 claims abstract description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229930186217 Glycolipid Natural products 0.000 claims abstract description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract description 3
- 102000004856 Lectins Human genes 0.000 claims abstract description 3
- 108090001090 Lectins Proteins 0.000 claims abstract description 3
- 108090001030 Lipoproteins Proteins 0.000 claims abstract description 3
- 102000004895 Lipoproteins Human genes 0.000 claims abstract description 3
- 229930182558 Sterol Natural products 0.000 claims abstract description 3
- 150000008065 acid anhydrides Chemical class 0.000 claims abstract description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 3
- 230000009435 amidation Effects 0.000 claims abstract description 3
- 238000007112 amidation reaction Methods 0.000 claims abstract description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims abstract description 3
- 229930183167 cerebroside Natural products 0.000 claims abstract description 3
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000001311 chemical methods and process Methods 0.000 claims abstract description 3
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 3
- 229920002549 elastin Polymers 0.000 claims abstract description 3
- 230000032050 esterification Effects 0.000 claims abstract description 3
- 238000005886 esterification reaction Methods 0.000 claims abstract description 3
- 229930182830 galactose Natural products 0.000 claims abstract description 3
- 150000002270 gangliosides Chemical class 0.000 claims abstract description 3
- 229960002442 glucosamine Drugs 0.000 claims abstract description 3
- 230000002414 glycolytic effect Effects 0.000 claims abstract description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000002523 lectin Substances 0.000 claims abstract description 3
- 239000003446 ligand Substances 0.000 claims abstract description 3
- 239000000693 micelle Substances 0.000 claims abstract description 3
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 3
- 150000003432 sterols Chemical class 0.000 claims abstract description 3
- 235000003702 sterols Nutrition 0.000 claims abstract description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 3
- 210000002421 cell wall Anatomy 0.000 claims abstract 5
- 230000035755 proliferation Effects 0.000 claims abstract 4
- 150000008163 sugars Chemical class 0.000 claims abstract 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 11
- 230000001276 controlling effect Effects 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 2
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 5
- 235000018102 proteins Nutrition 0.000 claims 5
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 claims 1
- PFRUBEOIWWEFOL-UHFFFAOYSA-N [N].[S] Chemical compound [N].[S] PFRUBEOIWWEFOL-UHFFFAOYSA-N 0.000 claims 1
- 150000001371 alpha-amino acids Chemical class 0.000 claims 1
- 235000008206 alpha-amino acids Nutrition 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 abstract description 7
- 230000008878 coupling Effects 0.000 abstract description 4
- 238000010168 coupling process Methods 0.000 abstract description 4
- 238000005859 coupling reaction Methods 0.000 abstract description 4
- 239000002253 acid Substances 0.000 abstract description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 abstract description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 abstract description 2
- 230000000593 degrading effect Effects 0.000 abstract description 2
- 102000016611 Proteoglycans Human genes 0.000 abstract 2
- 108010067787 Proteoglycans Proteins 0.000 abstract 2
- 239000000376 reactant Substances 0.000 abstract 2
- 150000008574 D-amino acids Chemical class 0.000 abstract 1
- 239000002174 Styrene-butadiene Substances 0.000 abstract 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 230000009137 competitive binding Effects 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000011115 styrene butadiene Substances 0.000 abstract 1
- 229920003048 styrene butadiene rubber Polymers 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 description 19
- 238000011161 development Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 14
- 239000002585 base Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 208000002064 Dental Plaque Diseases 0.000 description 9
- 210000003296 saliva Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000002925 dental caries Diseases 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 238000001212 derivatisation Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 208000007565 gingivitis Diseases 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 108010028144 alpha-Glucosidases Proteins 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 201000001245 periodontitis Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229940051866 mouthwash Drugs 0.000 description 3
- 230000007505 plaque formation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 208000003433 Gingival Pocket Diseases 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000002379 periodontal ligament Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 101100324465 Caenorhabditis elegans arr-1 gene Proteins 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 241001379910 Ephemera danica Species 0.000 description 1
- 208000034619 Gingival inflammation Diseases 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 108091007643 Phosphate carriers Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- JXBAVRIYDKLCOE-UHFFFAOYSA-N [C].[P] Chemical compound [C].[P] JXBAVRIYDKLCOE-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 208000019884 chronic gingivitis Diseases 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005661 deetherification reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/951,393 US5871714A (en) | 1997-10-16 | 1997-10-16 | Compositions for controlling bacterial colonization |
| PCT/US1998/021656 WO1999018999A1 (en) | 1997-10-16 | 1998-10-13 | Compositions for controlling bacterial colonization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200000422A1 EA200000422A1 (ru) | 2000-10-30 |
| EA002244B1 true EA002244B1 (ru) | 2002-02-28 |
Family
ID=25491643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200000422A EA002244B1 (ru) | 1997-10-16 | 1998-10-13 | Композиции для управления образованием бактериальных колоний |
Country Status (22)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020022005A1 (en) * | 1997-10-16 | 2002-02-21 | Budny John A. | Compositions for treating cystic fibrosis |
| US6830745B1 (en) * | 1997-10-16 | 2004-12-14 | Pharmacal Biotechnologies, Llc | Compositions for treating biofilm |
| US6159447A (en) * | 1997-10-16 | 2000-12-12 | Pharmacal Biotechnologies, Llc | Compositions for controlling bacterial colonization |
| US5972311A (en) * | 1998-01-26 | 1999-10-26 | Duke University | Method of preventing dental caries and other oral lesions |
| DE19909770A1 (de) | 1999-03-05 | 2000-09-07 | Werner Lubitz | Bakterienghosts als Träger- und Targetingvehikel |
| US8522127B2 (en) | 2001-07-16 | 2013-08-27 | Robert G. Adamson, III | Allowing operating system access to non-standard fonts in a network document |
| US10810355B1 (en) | 2001-07-16 | 2020-10-20 | Clantech, Inc. | Allowing operating system access to non-standard fonts in a network document |
| US7566447B2 (en) * | 2003-05-15 | 2009-07-28 | Iogenetics, Llc | Biocides |
| US8703134B2 (en) | 2003-05-15 | 2014-04-22 | Iogenetics, Llc | Targeted cryptosporidium biocides |
| US20050014932A1 (en) * | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| US8394379B2 (en) * | 2003-05-15 | 2013-03-12 | Iogenetics, Llc | Targeted cryptosporidium biocides |
| US7220405B2 (en) * | 2003-09-08 | 2007-05-22 | E. I. Du Pont De Nemours And Company | Peptide-based conditioners and colorants for hair, skin, and nails |
| WO2006132665A2 (en) * | 2004-10-20 | 2006-12-14 | Iogenetics, Llc | Biocides |
| CA2670899C (en) * | 2006-12-01 | 2016-11-22 | Laclede, Inc. | Use of hydrolytic and oxidative enzymes to dissolve biofilm in ears |
| JP5453260B2 (ja) * | 2007-07-25 | 2014-03-26 | スリーエム イノベイティブ プロパティズ カンパニー | 被膜形成歯科用組成物及び関連する方法 |
| JP5628031B2 (ja) | 2007-07-25 | 2014-11-19 | スリーエム イノベイティブ プロパティズ カンパニー | 治療用歯科用組成物及び関連する方法 |
| EP2092834A1 (en) * | 2008-02-19 | 2009-08-26 | Innopact B.V. | Methods and compositions of sphingolipid for preventing treating microbial infections |
| EP2655646A4 (en) | 2010-12-20 | 2014-05-21 | Du Pont | TARGETED PERHYDROLASES |
| ES2784495T3 (es) | 2010-12-20 | 2020-09-28 | Dupont Us Holding Llc | Generación enzimática de perácidos para su uso en productos para el cuidado bucodental |
| CN102219597B (zh) * | 2011-04-11 | 2013-09-11 | 北京中农瑞利源高科技发展有限公司 | 酶控剂和酶控系列肥料及其在农业中的应用 |
| US10420822B2 (en) | 2011-06-13 | 2019-09-24 | Ziolase, Llc | Compositions and methods to prevent and treat biofilms |
| US20120315260A1 (en) * | 2011-06-13 | 2012-12-13 | Svetlana A. Ivanova | Compositions and Methods to Prevent and Treat Biofilms |
| IN2012DE01792A (enrdf_load_stackoverflow) | 2012-06-11 | 2015-10-16 | Council Scient Ind Res | |
| KR102360720B1 (ko) * | 2015-06-30 | 2022-02-10 | (주)아모레퍼시픽 | 프라그 기질 용해제 |
| CN111551416B (zh) * | 2020-03-22 | 2021-08-06 | 华南理工大学 | 一种基于细胞膜磷脂酰丝氨酸荧光染色的细菌类凋亡评价方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1373487A (en) * | 1970-10-26 | 1974-11-13 | Guggenheim B | Enzymes their preparation and uses |
| US4335101A (en) * | 1971-08-10 | 1982-06-15 | Merck & Co., Inc. | Oral hygiene enzymes and method for preparation |
| JPS5536317B2 (enrdf_load_stackoverflow) * | 1972-04-22 | 1980-09-19 | ||
| GB1433593A (en) * | 1972-06-09 | 1976-04-28 | Royal College Of Surgeons | Conjugates |
| US4138476A (en) * | 1977-08-03 | 1979-02-06 | The United States Of America As Represented By The Secretary Of The Navy | Plaque dispersing enzymes as oral therapeutic agents by molecular alteration |
| JPS57165312A (en) * | 1981-04-03 | 1982-10-12 | Handai Biseibutsubiyou Kenkyukai | Production of oral composition |
| JPH0641424B2 (ja) * | 1984-11-06 | 1994-06-01 | ライオン株式会社 | う蝕予防剤 |
| US5306639A (en) * | 1985-03-20 | 1994-04-26 | Aizo Matsushiro | DNA encoding glucanase enzymes |
| US4737359A (en) * | 1985-04-18 | 1988-04-12 | Colgate-Palmolive Company | Control of dental plaque and caries using emulsan |
| GB8528761D0 (en) * | 1985-11-22 | 1985-12-24 | Axon Healthcare Ltd | Enzyme-coupled antibodies |
| WO1991000112A1 (en) * | 1989-06-30 | 1991-01-10 | Brunswick Corporation | Antibody-lactate oxidase conjugates |
| JPH0363215A (ja) * | 1989-07-29 | 1991-03-19 | Nakano Vinegar Co Ltd | 歯垢分解組成物 |
| AU642979B2 (en) * | 1990-03-21 | 1993-11-04 | Quest International B.V. | Utilization and delivery of enzymes |
| GB9021671D0 (en) * | 1990-10-05 | 1990-11-21 | Unilever Plc | Delivery of agents |
| AU642980B2 (en) * | 1990-03-21 | 1993-11-04 | Quest International B.V. | Ultilization of enzymes |
| US5202113A (en) * | 1990-04-30 | 1993-04-13 | The United States Of America As Represented By The Department Of Health And Human Services | Plaque-inhibiting protein from bacteroides loeschei and methods for using the same |
| US5362480A (en) * | 1991-12-31 | 1994-11-08 | Lever Brothers Company, Division Of Conopco, Inc. | Oral hygiene compositions containing amino sugars as antiplaque agents |
| US5409902A (en) * | 1991-12-31 | 1995-04-25 | Lever Brothers Company | Oral hygiene compositions containing glyceroglycolipids as antiplaque compounds |
| US5320831A (en) * | 1992-12-30 | 1994-06-14 | The Procter & Gamble Company | Oral compositions |
| US5490978A (en) * | 1993-10-15 | 1996-02-13 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Block copolymers of polysaccharides and polyalkylene oxides |
| EP0824019B1 (en) * | 1996-08-13 | 2002-11-20 | Quest International B.V. | Inhibition or reduction of oral malodour |
-
1997
- 1997-10-16 US US08/951,393 patent/US5871714A/en not_active Expired - Lifetime
-
1998
- 1998-10-02 ZA ZA989024A patent/ZA989024B/xx unknown
- 1998-10-13 IL IL13562898A patent/IL135628A0/xx unknown
- 1998-10-13 HU HU0100016A patent/HUP0100016A2/hu unknown
- 1998-10-13 ID IDW20000675A patent/ID24368A/id unknown
- 1998-10-13 EA EA200000422A patent/EA002244B1/ru not_active IP Right Cessation
- 1998-10-13 WO PCT/US1998/021656 patent/WO1999018999A1/en not_active Application Discontinuation
- 1998-10-13 NZ NZ503974A patent/NZ503974A/en unknown
- 1998-10-13 TR TR2000/00988T patent/TR200000988T2/xx unknown
- 1998-10-13 CZ CZ20001237A patent/CZ20001237A3/cs unknown
- 1998-10-13 JP JP2000515630A patent/JP2001519404A/ja active Pending
- 1998-10-13 CA CA002306459A patent/CA2306459A1/en not_active Abandoned
- 1998-10-13 CN CN98810256A patent/CN1276732A/zh active Pending
- 1998-10-13 AU AU98028/98A patent/AU742762B2/en not_active Ceased
- 1998-10-13 BR BR9812923-6A patent/BR9812923A/pt not_active IP Right Cessation
- 1998-10-13 EP EP98952294A patent/EP1023084A1/en not_active Withdrawn
- 1998-10-13 PL PL98339900A patent/PL339900A1/xx unknown
- 1998-10-13 KR KR1020007003979A patent/KR20010015757A/ko not_active Withdrawn
-
2000
- 2000-04-12 CU CU20000079A patent/CU22838A3/es unknown
- 2000-04-12 NO NO20001885A patent/NO20001885L/no not_active Application Discontinuation
- 2000-04-13 MX MXPA00003618 patent/MXPA00003618A/es unknown
-
2002
- 2002-09-02 IN IN891DE2002 patent/IN2002DE00891A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1023084A1 (en) | 2000-08-02 |
| WO1999018999A1 (en) | 1999-04-22 |
| TR200000988T2 (tr) | 2000-08-21 |
| NZ503974A (en) | 2002-05-31 |
| CU22838A3 (es) | 2006-04-18 |
| CZ20001237A3 (cs) | 2000-08-16 |
| AU742762B2 (en) | 2002-01-10 |
| CN1276732A (zh) | 2000-12-13 |
| ID24368A (id) | 2000-07-13 |
| EA200000422A1 (ru) | 2000-10-30 |
| JP2001519404A (ja) | 2001-10-23 |
| CA2306459A1 (en) | 1999-04-22 |
| AU9802898A (en) | 1999-05-03 |
| PL339900A1 (en) | 2001-01-15 |
| BR9812923A (pt) | 2000-08-08 |
| NO20001885D0 (no) | 2000-04-12 |
| IL135628A0 (en) | 2001-05-20 |
| US5871714A (en) | 1999-02-16 |
| IN2002DE00891A (enrdf_load_stackoverflow) | 2005-01-21 |
| KR20010015757A (ko) | 2001-02-26 |
| ZA989024B (en) | 1999-04-07 |
| NO20001885L (no) | 2000-06-14 |
| HUP0100016A2 (hu) | 2001-05-28 |
| MXPA00003618A (es) | 2001-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA002244B1 (ru) | Композиции для управления образованием бактериальных колоний | |
| US6159447A (en) | Compositions for controlling bacterial colonization | |
| AU1424399A (en) | Pharmaceutical composition comprising phosphatase or a derivative thereof | |
| Dipalma et al. | Focus on the cariogenic process: Microbial and biochemical interactions with teeth and oral environment | |
| Golub et al. | Enhanced collagenase activity in diabetic rat gingiva: in vitro and in vivo evidence | |
| KR100264623B1 (ko) | 인슐린-유사 작용을 하는 포스포이노시톨-글리칸-펩타이드 및 이의 제조방법 | |
| Arnett | Osteoclast biology | |
| US4767615A (en) | Dental therapy by vesicle delivery | |
| JP2003521483A (ja) | ヒトラクトフェリンの第１カチオンクラスターの抗菌活性 | |
| JP3802721B2 (ja) | 生体コラーゲン合成促進剤 | |
| Sterrett | The osteoclast and periodontitis | |
| US5821226A (en) | BAL C-tail drug delivery molecules | |
| Shashikiran et al. | The Emergence of Peptides and Dendrimers in Dentistry | |
| HK1033093A (en) | Compositions for controlling bacterial colonization | |
| EP4480958A1 (en) | Peptide having antibacterial, anti-inflammatory or tissue regeneration ability and use thereof | |
| de Barros Morais Cardoso et al. | Role of Saliva in Oral Biofilm Models | |
| WO2000047175A1 (en) | Oral compositions and methods of production thereof | |
| Guirado | Roles of the Phosphate-Regulating Proteins, PHEX and DMP1, in the Dentin Matrix of XLH | |
| Khayat | Strategies to Treat Periodontal Tissues and Regenerate Pulp-Dentin Complex | |
| Lassila | Effect of occlusal disorder on the gingiva in rats with experimental arteriosclerosis: Enzyme histochemical and biochemical study | |
| Oliver et al. | 2. The Effect oE Topical Applicatioo of Chlorhexidine on Subgiogival Microbial Colonization | |
| Yamashita et al. | The Application of Bovine Submaxillary Gland Mucin (BSM) to Skin Care Cosmetics | |
| Reddi | Modulation of cytokine synthesis by bacterial components | |
| Erickson | Characterization of the platelet aggregation-associated protein from Streptococcus sanguis | |
| Gingerich | CURRENT PAPERS IN ORAL BIOLOGY (28690-28793) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |